Drug Profile
GSK 3888550A
Alternative Names: GSK3888550A; GSK3888550A RSV maternal vaccine; RSV-MAT; RSVPreF3; Unadjuvanted RSV maternal vaccine - GSKLatest Information Update: 24 Apr 2024
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Respiratory syncytial virus infections
Most Recent Events
- 24 Apr 2024 GlaxoSmithKline plans a phase III trial for Respiratory syncytial virus infections (Combination therapy, Prevention, In adults, In the elderly) in USA, Belgium, Netherlands and Spain (IM, Injection) in April 2024 (NCT06374394) (EudraCT2023-510196-59-00)
- 28 Nov 2023 GlaxoSmithKline terminates a phase III trial in Respiratory syncytial virus infections (Prevention) in Brazil, Canada, Finland, India, Italy, Panama, South Africa, Spain and USA based on the recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009) (IM) (NCT04980391)
- 11 Sep 2023 GlaxoSmithKline terminates the phase III trial in Respiratory syncytial virus infections (Prevention) in Argentina, Australia, Bangladesh, Belgium, Brazil, Canada, Colombia, Dominican Republic, Finland, France, Honduras, India, Italy, Mexico, New Zealand, Panama, Philippines, South Africa, South Korea, Spain, Taiwan, Thailand, United Kingdom and USA based on the recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009) (IM) (NCT04605159)